Zevra Therapeutics (ZVRA) Share-based Compensation (2014 - 2026)

Zevra Therapeutics' Share-based Compensation history runs 13 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• Quarterly Share-based Compensation fell 15.41% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (down 23.57% YoY) and the FY2025 annual result came in at $12.6 million, down 15.24% from the prior year.
• Share-based Compensation was $2.6 million for Q1 2026 at Zevra Therapeutics, down from $4.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $6.1 million in Q3 2024 and bottomed at $591000.0 in Q1 2023.
• A 5-year average of $2.4 million and a median of $2.3 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 374.84% — and 2025, when it plunged 54.85%.
• Zevra Therapeutics' Share-based Compensation stood at $911000.0 in 2022, then surged by 61.58% to $1.5 million in 2023, then soared by 172.96% to $4.0 million in 2024, then advanced by 6.62% to $4.3 million in 2025, then plunged by 38.49% to $2.6 million in 2026.
• Business Quant data shows ZVRA's Share-based Compensation at $2.6 million in Q1 2026, $4.3 million in Q4 2025, and $2.8 million in Q3 2025.